Skip to content
Screener

Ionis Pharmaceuticals IONS Gain (loss) on disposal of assets

Gain (loss) on disposal of assets at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$19M
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$329K-75.4%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$11.75M+1,152%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.4B+44.4%
Enterprise value$9.31B+32.9%
P/S10.8×+3.9×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnInvestments.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000874015-26-000251
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Investment income20,23024,68745,71349,354
Interest expense(4,618)(4,114)(9,778)(8,223)
Interest expense related to sale of future royalties(17,506)(18,648)(34,843)(37,470)
Gain (loss) on investments, net(10,182)(18,312)12,401(20,476)
Other income, net987102529569
Income (loss) before income tax benefit (expense)(113,382)123,531(205,692)(23,291)
Income tax benefit (expense)(1,264)20(1,482)(96)
Net income (loss)$$(114,646)$123,551$(207,174)(23,387)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ionis Pharmaceuticals's gain (loss) on disposal of assets?
Ionis Pharmaceuticals (IONS) reported gain (loss) on disposal of assets of -$10.18M in Q2 2026.
How has Ionis Pharmaceuticals's gain (loss) on disposal of assets changed year-over-year?
Ionis Pharmaceuticals's gain (loss) on disposal of assets increased by 44.4% year-over-year, from -$18.31M to -$10.18M.
What does gain (loss) on disposal of assets mean?
Gains or losses recognized on the disposal of businesses, property, equipment, investments, or other assets at prices above or below their carrying value.

Ask your AI about Ionis Pharmaceuticals's gain (loss) on disposal of assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude